Hainan Haiyao unit gains approval for stomach drug

Hainan Haiyao Co., Ltd. [SZSE:000566] announced that its wholly-owned subsidiary, Haikou Pharmaceutical Factory Co., Ltd., has received approval from the National Medical Products Administration for its supplemental application regarding Fengliao Changweikang dispersible tablets. With this approval, Haikou Pharmaceutical Factory becomes the marketing authorization holder for the drug. The approval allows Haikou Pharmaceutical Factory to replace Hainan Huigu Pharmaceutical Co., Ltd. as the official marketing authorization holder. The drug's formula, production processes, and quality standards remain unchanged. Fengliao Changweikang dispersible tablets are used to treat acute gastroenteritis and related digestive issues. The company expects this approval to enhance its existing line of Fengliao Changweikang products and improve its overall market competitiveness.